期刊文献+

重新认识氨曲南在产ESBLs大肠埃希菌感染中的治疗地位

Re-understanding of the treatment status of aztreonam in ESBLs-producing Escherichia coli
下载PDF
导出
摘要 目的探讨氨曲南对产ESBLs大肠埃希菌所致感染的疗效。方法临床药师参与1例氨曲南敏感的产ESBLs大肠埃希菌引起脓毒症的抗感染治疗全过程,进行用药分析与干预。结果患者使用氨曲南治疗产ESBLs大肠埃希菌引起的脓毒症效果良好。结论并非所有产ESBLs肠杆菌科细菌感染都必须选择碳青霉烯类,部分患者可根据药敏结合患者病情选择性使用氨曲南。 Objective To investigate the treatment effect of aztreonam on the infection caused by ESBLsproducing E.coli. Methods Clinical pharmacists participated in the anti-infection treatment of sepsis caused by aztreonam-sensitive ESBLs-producing E.coli,and used drug analysis and intervention. Results Treatment with aztreonam successfully controlled sepsis caused by ESBLs-producing E. coli. Conclusion Not all of ESBLs-producing Enterobacteriaceae bacterial infections must be selected for carbapenems. Some patients may be treated with aztreonam according to the drug susceptibility and the patients condition.
作者 谢奕丹 XIE Yidan(Pharmacy Department Guangdong Provincial Hospital of Integrated Traditional Chinaese and Western Medicine Foshan 528200 China)
出处 《广东药科大学学报》 CAS 2018年第3期357-359,共3页 Journal of Guangdong Pharmaceutical University
关键词 氨曲南 超广谱β-内酰胺酶(ESBLs) 碳青霉烯类 大肠埃希菌 aztreonam extended-spectrum beta-lactamases ESBLs carbapenems Escherichia coli
  • 相关文献

参考文献3

二级参考文献69

  • 1季淑娟,顾怡明,谭文涛,王丹丹,冯羡菊,周志慧,俞云松,陈亚岗,李兰娟.中国部分地区大肠埃希菌和肺炎克雷伯菌超广谱β内酰胺酶基因型研究[J].中华检验医学杂志,2004,27(9):590-593. 被引量:172
  • 2俞云松.超广谱β-内酰胺酶研究进展[J].中华医学杂志,2006,86(9):641-644. 被引量:95
  • 3汪复.2005中国CHINET细菌耐药性监测结果[J].中国感染与化疗杂志,2006,6(5):289-295. 被引量:284
  • 4Poirel L,Heritier C,Tolun V,etal. Emergence of oxacillinase- mediated resistance to imipenem in Klebsilla pneumoniae [J]. Antimierob Agents Chemother, 2004,48( 1 ) : 15 -22.
  • 5Jan W R, Niels H. OXA-type carbapenemases [J]. J Antimicrob Chemother,2006,57(3) :373 - 383.
  • 6Danel F, Hall L M, Livermore D M. Laboratory mutants of OXA-10 β-laetamase giving ceftazidime resistance in Pseudomonas aeruginosa [J]. J Antimicrob Chemother, 1999,43(3) : 339 - 344.
  • 7Weldhagen G,Poirel L, Nordmann P. Ambler class A extend ed spectrum beta lactamases in Pseudomonas aeruginosa : novel developments and clinical impact [J]. Antimicrob Agents Chemother,2003,47(8) :2385 - 2392.
  • 8Boo T W, Walsh F, Crowley B. First report of OXA~23 carbapenemase in clinical isolates of Acinetobacter species in the Irish Republic [J]. J Antimicrob Chemother, 2006,58(5):1101 - 1102.
  • 9Siu L K, Lo J Y, Yuen K Y, et al.β-lactamases in Shigella flexneri solates from Hong Kong and Shanghai and a Novel OXA-l-like ~-lactamase, OXA-30 [ J ]. Antimicrob Agents Chemother,2000,44(8) :2034 -2038.
  • 10Hail L M,Livermore D M, Gur D, et al. OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) beta lactamase from Pseudomonasaeruginosa [J]. Antimicrob Agents Chemother, 1993,37(8) : 1637 - 1644.

共引文献267

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部